Stock Events

Stock Events

enGene Therapeutics 

€6.04
0
+€0+0% Friday 06:10

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12JunExpected
Q4 2025
Next
-0.48
-0.45
-0.41
-0.38
Expected EPS
-0.4050467408
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow S0N0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, overlapping with enGene's focus on gene therapy for gastrointestinal diseases.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, which competes directly with enGene's gene therapy technologies.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is known for its work in CRISPR-Cas9 gene editing, a technology that can be applied similarly to enGene's gene delivery platforms.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is another key player in the CRISPR gene editing sector, directly competing with enGene's approach to gene therapy.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, similar to enGene's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, a field closely related to gene therapy, impacting similar therapeutic areas as enGene.
Ionis Pharmaceuticals
IONS
Mkt Cap12.35B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, competing in the broader genetic medicine space with enGene.
uniQure N.V.
QURE
Mkt Cap1.07B
uniQure is involved in developing gene therapies for patients with severe genetic diseases, directly competing with enGene's therapeutic approaches.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the same innovative sector as enGene.

About

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Show more...
CEO
Mr. Ronald H. W. Cooper
Employees
56
Country
US
ISIN
CA29286X1015
WKN
000A425M8

Listings

F
DE
S0N0.F
F
DE
S0N.F
XNAS
US
ENGNW
XNAS
US
ENGN

0 Comments

Share your thoughts

FAQ

What is enGene Therapeutics stock price today?▼
The current price of S0N0.F is €6.04 EUR — it has increased by +0% in the past 24 hours. Watch enGene Therapeutics stock price performance more closely on the chart.
What is enGene Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange enGene Therapeutics stocks are traded under the ticker S0N0.F.
When is the next enGene Therapeutics earnings date?▼
enGene Therapeutics is going to release the next earnings report on June 12, 2026.
What were enGene Therapeutics earnings last quarter?▼
S0N0.F earnings for the last quarter are -0.38 EUR per share, whereas the estimation was -0.48 EUR resulting in a +21.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does enGene Therapeutics have?▼
As of April 11, 2026, the company has 56 employees.
In which sector is enGene Therapeutics located?▼
enGene Therapeutics operates in the Health Care sector.
When did enGene Therapeutics complete a stock split?▼
enGene Therapeutics has not had any recent stock splits.
Where is enGene Therapeutics headquartered?▼
enGene Therapeutics is headquartered in Montreal, US.